Suppr超能文献

在治疗哮吼时,布地奈德与口服地塞米松联合使用并无优势。

Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup.

作者信息

Geelhoed Gary Cornelis

机构信息

Emergency Department, Princess Margaret Hospital for Children, Perth, WA, Australia.

出版信息

Pediatr Emerg Care. 2005 Jun;21(6):359-62. doi: 10.1097/01.pec.0000166724.99555.de.

Abstract

OBJECTIVE

To evaluate the effect of adding inhaled budesonide (2 mg) to oral dexamethasone 0.15 mg/kg in children hospitalized with croup.

SETTING

Observation ward of a Tertiary Paediatric Hospital Emergency Department.

SUBJECTS

Seventy-two children (age range 3 to 126 months) hospitalized with croup.

INTERVENTION

Children randomized to receive either 2 mg of nebulized budesonide or placebo, with all children receiving a single oral dose of 0.15 mg/kg dexamethasone.

OUTCOME MEASURES

Primary outcome was duration of hospital stay. Other measures included croup scores from 0 to 12 hours, use of nebulized epinephrine, duration of croup symptoms, duration of viral symptoms, and return to medical care for croup or for any other reason following discharge from hospital.

RESULTS

Baseline characteristics for the 2 groups were similar. There was no difference in time to discharge for the 2 groups or for other outcome measures with a risk ratio of 1.3 (95% confidence intervals of 0.82 and 2.1).

CONCLUSIONS

The addition of inhaled budesonide (2 mg) to oral dexamethasone (0.15 mg/kg) offers no advantage in the treatment of children hospitalized with croup.

摘要

目的

评估在接受口服地塞米松0.15mg/kg治疗的喉炎住院儿童中加用吸入性布地奈德(2mg)的效果。

地点

一家三级儿科医院急诊科的观察病房。

研究对象

72名喉炎住院儿童(年龄范围3至126个月)。

干预措施

将儿童随机分为接受2mg雾化布地奈德或安慰剂治疗,所有儿童均接受单次口服剂量0.15mg/kg的地塞米松。

观察指标

主要观察指标为住院时间。其他指标包括0至12小时的喉炎评分、雾化肾上腺素的使用情况、喉炎症状持续时间、病毒症状持续时间以及出院后因喉炎或其他原因再次就医的情况。

结果

两组的基线特征相似。两组的出院时间或其他观察指标均无差异,风险比为1.3(95%置信区间为0.82至2.1)。

结论

在口服地塞米松(0.15mg/kg)基础上加用吸入性布地奈德(2mg)对喉炎住院儿童的治疗并无优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验